This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meropol, N. J. Articles by Schulman, K. A. Search for Related Content PubMed PubMed Citation Articles by Meropol, N. J. Articles by Schulman, K. A.

Cost of Cancer Care: Issues and Implications

Neal J. Meropol, Kevin A. Schulman

From the Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, PA; and the Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC

Address reprint requests to Neal J. Meropol, MD, Fox Chase Cancer Center, 333 Cottman Ave, Room C307, Philadelphia, PA 19111; e-mail: neal.meropol{at}fccc.edu

Medical technology is increasingly costly in most fields of clinical medicine. Oncology has not been spared from issues related to cost, in part resulting from the tremendous scientific progress that has lead to new tools for diagnosis, treatment, and follow-up of our patients. The increasing cost of health care in general (and cancer care in particular) raises complex questions related to its effects on our economy and the citizens of our society. This article reviews the macroeconomic principles and individual behaviors that govern medical spending, and examines how cost disproportionately affects various populations. Our overall goal is to frame debate about health policy concerns that influence the clinical practice of oncology.

Presented in part in written format in the 2005 Ameican Society of Clinical Oncology Educational Book.

Authors' discolsures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				J. McFarlane, J. Riggins, and T. J. Smith SPIKE$: A Six-Step Protocol for Delivering Bad News About the Cost of Medical Care J. Clin. Oncol., September 1, 2008; 26(25): 4200 - 4204. [Full Text] [PDF]

				Y.-C. T. Shih and M. T. Halpern Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean? CA Cancer J Clin, July 1, 2008; 58(4): 231 - 244. [Abstract] [Full Text] [PDF]

				I. Hozo and B. Djulbegovic When Is Diagnostic Testing Inappropriate or Irrational? Acceptable Regret Approach Med Decis Making, July 1, 2008; 28(4): 540 - 553. [Abstract] [PDF]

				S. E. Harrington and T. J. Smith The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?" JAMA, June 11, 2008; 299(22): 2667 - 2678. [Abstract] [Full Text] [PDF]

				R. J. Mayer Should Capecitabine Replace Infusional Fluorouracil and Leucovorin When Combined With Oxaliplatin in Metastatic Colorectal Cancer? J. Clin. Oncol., September 20, 2007; 25(27): 4165 - 4167. [Full Text] [PDF]

				N. J. Meropol and K. A. Schulman In Reply J. Clin. Oncol., August 1, 2007; 25(22): 3383 - 3383. [Full Text] [PDF]

				N. J. Meropol and K. A. Schulman Perspectives on the Cost of Cancer Care J. Clin. Oncol., January 10, 2007; 25(2): 169 - 170. [Full Text] [PDF]

				P. A. Grusenmeyer and Y.-N. Wong Interpreting the Economic Literature in Oncology J. Clin. Oncol., January 10, 2007; 25(2): 196 - 202. [Abstract] [Full Text] [PDF]